Neurology(R) neuroimmunology & neuroinflammation · 2026
Shared Epitope-Positive HLA Alleles Protect Against Alpha-Synuclein Pathology in a Model of Parkinson Disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Carver Jonathan J, Pugh Bryce A, Ma Qin, Caillier Stacy J, Denbrock Rachael R, Martines Cindy C, Puckett Alexandra E, Roberson Taylor C, Fernandez-Viña Marcelo A, Hollenbach Jill A, Oksenberg Jorge, Holoshitz Joseph, Didonna Alessandro
Аннотация
BACKGROUND AND OBJECTIVE: There is increasing evidence that human leukocyte antigen (HLA) allelic variants play a role in the genetic predisposition to Parkinson disease (PD). In this regard, we have recently reported that the HLA-DRB1*04:01 allele, typified by residues Q/R-K/R-R-A-A at positions 70-74 in the HLA-DRβ1 chain in combination with valine at position 11 (11-V), confers moderate protective effects. In this study, we tested whether HLA-DRB1*04:01 can modulate PD pathology in vivo.
METHODS: We induced the alpha-synuclein preformed fibrils seeding PD model in humanized mice expressing the HLA-DRB1*04:01 or HLA-DRB1*04:02 allele. We then performed a comprehensive histopathologic and molecular characterization of the main disease phenotypes by combining quantitative histopathology, RNA-sequencing, flow cytometry immunophenotyping, and cytokine profiling.
RESULTS: Mice expressing HLA-DRB1*04:01 display limited alpha-synuclein aggregation and lower dopaminergic axonal injury compared with mice expressing HLA-DRB1*04:02, along with reduced systemic inflammation. We also show that the microglia compartment in HLA-DRB1*04:01 mice is in an activated steady state, possibly suggesting their mechanistic involvement in alpha-synuclein clearance.
DISCUSSION: Altogether, our findings provide the first experimental evidence of the genetic association between the HLA locus and PD susceptibility and support a neuroprotective function for the HLA-DRB1*04:01 allele against alpha-synuclein pathology.
METHODS: We induced the alpha-synuclein preformed fibrils seeding PD model in humanized mice expressing the HLA-DRB1*04:01 or HLA-DRB1*04:02 allele. We then performed a comprehensive histopathologic and molecular characterization of the main disease phenotypes by combining quantitative histopathology, RNA-sequencing, flow cytometry immunophenotyping, and cytokine profiling.
RESULTS: Mice expressing HLA-DRB1*04:01 display limited alpha-synuclein aggregation and lower dopaminergic axonal injury compared with mice expressing HLA-DRB1*04:02, along with reduced systemic inflammation. We also show that the microglia compartment in HLA-DRB1*04:01 mice is in an activated steady state, possibly suggesting their mechanistic involvement in alpha-synuclein clearance.
DISCUSSION: Altogether, our findings provide the first experimental evidence of the genetic association between the HLA locus and PD susceptibility and support a neuroprotective function for the HLA-DRB1*04:01 allele against alpha-synuclein pathology.